Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With

Rhea-AI Summary

Agenus Inc. (NASDAQ: AGEN) announced that Dr. Jennifer Buell, President and COO, participated in a fireside chat series with Scientific American on September 16, 2020. Dr. Buell discussed Agenus’ immunotherapy innovations in combating COVID-19, emphasizing the significance of combination therapies and improving patient access. The replay of the event is accessible online. Agenus, a clinical-stage immuno-oncology company, aims to enhance patient outcomes through a variety of therapeutic approaches, including antibody therapeutics and cancer vaccine platforms.

Positive

• Engagement in public discussions highlighting innovative therapies against COVID-19.
• Focus on combination therapies which may lead to improved patient outcomes.
• Access to a replay of the informative chat to reach a broader audience.

Negative

• None.

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, spoke to Jeremy Abbate, Publisher of Scientific American, in its inaugural fireside chat series 18 Minutes With on Wednesday September 16, 2020 at 4:00 p.m. EDT.

A replay of the live streaming event 18 Minutes With: Dr. Jennifer Buell is available at https://www.scientificamerican.com/custom-media/cancer-covid-19-and-access-to-combination-therapies/

In the interview with Jeremy Abbate, Dr. Buell discusses Agenus’ immunotherapies in the fight against COVID-19, the importance of combination therapies and the need for improved patient access, and the rapidly changing I-O landscape.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:

Agenus Inc. 
Jennifer Buell, PhD
781-674-4420 
Jennifer.Buell@agenusbio.com

FAQ

What did Dr. Jennifer Buell discuss in the Scientific American fireside chat?

Dr. Buell discussed Agenus' immunotherapies for COVID-19, the importance of combination therapies, and improving patient access.

When was the interview with Dr. Jennifer Buell conducted?

The interview took place on September 16, 2020.

Where can I find the replay of Dr. Buell's interview?

The replay of the interview is available online at Scientific American's website.

What is the focus of Agenus as an immuno-oncology company?

Agenus focuses on developing therapies that engage the immune system to fight cancer and improve patient populations' access to immunotherapy.

What does AGEN stand for?

AGEN is the stock symbol for Agenus Inc., an immuno-oncology company.